Emergence of daptomycin non-susceptible coagulase-negative Staphylococci in patients with cardiovascular device infections: Two cases report investigated by whole genome analysis

RATIONALE: Daptomycin (DAP) is a key drug for treating severe Staphylococcus infections. The emergence of DAP non-susceptible Staphylococcus aureus has been widely recognized in clinical situations, although the clinical status of DAP non-susceptible coagulase-negative Staphylococcus (CoNS) infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiya, Hideharu, Sugawara, Yo, Kimura, Keigo, Hamaguchi, Shigeto, Nishi, Isao, Hayashi, Masahiro, Akeda, Yukihiro, Tomono, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310605/
https://www.ncbi.nlm.nih.gov/pubmed/30544442
http://dx.doi.org/10.1097/MD.0000000000013487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310605/
https://www.ncbi.nlm.nih.gov/pubmed/30544442
http://dx.doi.org/10.1097/MD.0000000000013487

Ejemplares similares